Iodine-131 rituximab radioimmunotherapy with BEAM conditioning and autologous stem cell transplant salvage therapy for relapsed/refractory aggressive non-hodgkin lymphoma

Cancer Biotherapy and Radiopharmaceuticals

Volumn 27, Issue 9, 2012, Pages 552-560

  Kruger, Paul C ^a   Cooney, Julian P ^b   Turner, J Harvey ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

Author keywords

Bone marrow transplant; Conditioning; Lymphoma; Radioimmunotherapy

Indexed keywords

CARMUSTINE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; LORAZEPAM; MELPHALAN; ONDANSETRON; PROMETHAZINE; RITUXIMAB I131; UNCLASSIFIED DRUG; VALACICLOVIR;

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER RECURRENCE; CANCER REGRESSION; CLINICAL ARTICLE; DISEASE ACTIVITY; DISEASE FREE SURVIVAL; DOSIMETRY; ENGRAFTMENT; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; LARGE CELL LYMPHOMA; MALE; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NEUTROPHIL COUNT; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TREATMENT RESPONSE; WHOLE BODY RADIATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; CYTARABINE; DISEASE-FREE SURVIVAL; ETOPOSIDE; HUMANS; IODINE RADIOISOTOPES; LYMPHOMA, NON-HODGKIN; MELPHALAN; MIDDLE AGED; RADIOIMMUNOTHERAPY; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 84868278743     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2012.1275     Document Type: Article

References (71)

1. Pearce N, Bethwaite P. Increasing incidence of non-Hodgkin's lymphoma: Occupational and environmental factors. Cancer Res 1992;52:5496s.
2. Muller AMS, Ihorst G, Mertelsmann R, et al. Epidemiology of non-Hodgkin's lymphoma (NHL): Trends, geographic distribution, and etiology. Ann Hematol 2005;84:1.
3. Rosenberg SA. Autologous bone marrow transplantation in non-Hodgkin's lymphoma. N Engl J Med 1987; 316:1541.
4. Philip T, Armitage JO, Spitzer G, et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediategrade or high grade non-Hodgkin's lymphoma. N Engl J Med 1987;316:1493.
5. Philip T, Chauvin F, Armitage J, et al. Parma International Protocol: Pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous Bone marrow transplantation. Blood 1991;77:1587.
6. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) Anti-CD20 monoclonal antibody therapy in patients with relapsed low grade non-Hodgkin's lymphoma. Blood 1997;90:2188.
7. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417.
8. Hiddemann W, Kneba M, Dreyling M, et al. Front-line therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) significantly improves the outcome of patients with advanced-stage follicular lymphomas compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group. Blood 2005;106:3725.
9. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379.
10. Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B cell lymphoma in British Columbia. J Clin Oncol 2005;23:5027.
11. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010; 28:4184.
12. Cheson BD. Time to remember to forget dose-intensification in lymphoma. J Clin Oncol 2011;29:3954.
13. Kaminski MS, Zasadny KR, Francis IR, et al. Radioimmunotherapy of B-cell lymphoma with 131I anti-B1 (anti-CD20) antibody. N Engl J Med 1993;329:459.
14. Press OW. Evidence mounts for the efficacy of radioimmunotherapy for B-cell lymphomas. J Clin Oncol 2008; 26:5147.
15. Leahy MF, Seymour JF, Hicks RJ, et al. Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma. J Clin Oncol 2006;24:4418.
16. Rao AV, Akabani G, Rizzieri DA. Radioimmunotherapy for non-Hodgkin's lymphoma. Clin Med Res 2005;3:157.
17. Leahy MF, Turner JH. Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131-I-rituximab in routine clinical practice: 10 year single institution experience of 142 consecutive patients. Blood 2011;117:45.
18. Gopal AK, Guthrie KA, Rajendran J, et al. 90Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma. Blood 2011;118: 1132.
19. Devizzi L, Guidetti A, Tarella C, et al. High-dose Yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: An outpatient preparative regimen for autologous hematopoietic cell transplantation. J Clin Oncol 2008;26: 5175.
20. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002;20:2453.
21. Nademanee A, Forman S, Molina A, et al. A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 2005;106:2896.
22. Krishnan A, Nademanee A, Fung HC, et al. Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 2008;26:90.
23. Shimoni A, Avivi I, Rowe JM, et al. A randomised study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma. Cancer 2012 [Epub ahead of print]; DOI: 10.1002/cncr.27418.
24. Winter JN, Inwards DJ, Spies S, et al. Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2009; 27:1653.
25. Press OW, Eary JF, Gooley T, et al. A phase I/II trial of iodine-131 tositumomab (anti-CD20), etoposide cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 2000;96:2934.
26. Vose JM, Bierman PJ, Enke C, et al. Phase I trial of iodine-131 tositumomab with high dose chemotherapy and autologous stem cell transplantation for relapsed non-Hodgkin's lymphoma. J Clin Oncol 2005;23:461.
27. Vose JM, Carter SL, Burns LJ, et al. Randomized phase III Trial of 131iodine-tositumomab (Bexxar)/carmustine, etoposide, cytarabine, melphalan (BEAM) vs. rituximab/BEAM and autologous stem cell transplantation for relapsed diffuse large B-cell lymphoma (DLBCL): No difference in progression-free (PFS) or overall survival (OS). ASH 2011; Abstract 661.
28. Bishton MJ, Leahy MF, Hicks RJ, et al. Repeat treatment with iodine-131-rituximab is safe and effective in patients with relapsed indolent B-cell non-Hodgkin's lymphoma who had previously responded to iodine-131-rituximab. Ann Oncol 2008;19:1629.
29. Delbeke D, Stroobants S, de Kerviler E, et al. Expert opinions on positron emission tomography and computed tomography imaging in lymphoma. Oncologist 2009;14(suppl2):30.
30. National Cancer Institute. NCI Common Terminology Criteria for Adverse Events
31. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B cell lymphoma. N Engl J Med 2002;346:235.
32. Kantarjian H, O'Brien S, Beran M, et al. Update of the Hyper-CVAD program in newly-diagnosed adult acute lymphoblastic leukemia. Blood 1995;86(suppl1, abstr):173a.
33. Luce JK, Gamble JF, Wilson HE, et al. Combined cyclophosphamide, vincristine, and prednisolone therapy of malignant lymphoma. Cancer 1971;28:306.
34. Kewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE (RICE) as second-line therapy prior to autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004;103:3684.
35. Herrmann RP, Rule SAJ, Davies JM, et al. Substitution of carboplatin for cisplatin in the DHAP (PARMA) regimen is effective salvage therapy in relapsed lymphoma [abstr]. International Symposium of Experimental Haematology, 1994.
36. Moskowitz CH, Bertino JR, Glassman JR, et al. Ifosfamide, Carboplatin, and Etoposide: A highly effective cytoreduction and peripheral-blood progenitor-cell mobilisation regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 1999;17:3776.
37. McKelvey EM, Gottlieb JA, Wilson HE, et al. Hydroxydaunomycin (adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976;38:1484.
38. Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988;71:117.
39. Sonneveld P, Michiels JJ. Full dose chemotherapy in elderly patients with non-Hodgkin's lymphoma: A feasibility study using a mitoxantrone containing regimen. Br J Cancer 1990;62:105.
40. Al-Ismail SAD, Whittaker JA, Gough J. Combination chemotherapy including epirubicin for the management of non-Hodgkin's lymphoma. Eur J Clin Oncol 1987;23:1379.
41. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987.
42. Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2007;111:558.
43. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258.
44. Herrmann RP, Trent M, Cooney J, et al. Infections in patients managed at home during autologous stem cell transplantation for lymphoma and multiple myeloma. Bone Marrow Transplant 1999;24:1213.
45. Herrmann RP, Leather M, Leather HL, et al. Clinical care for patients receiving autologous hematopoietic stem cell transplantation in the home setting. Oncol Nursing Forum 1998;25:1427.
46. Smith SM, Le Beau MM, Huo D, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: The University of Chicago series. Blood 2003;102:43.
47. Pardanani A, Tefferi A. Cytogenetic risk stratification in myelodysplastic syndromes: Are we there yet? J Clin Oncol 2012;30:2703.
48. Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomised study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: A study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010; 116:2040.
49. Keating GM. Rituximab: A review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs 2010;70:1445.
50. Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006; 108:4003.
51. van Oers MH, Van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: Long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 2010;28:2853.
52. Buchegger F, Antonescu C, Delaloye AB, et al. Long term complete responses after 131I-toxitumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma. Br J Cancer 2006;94:1770.
53. Gopal AK, Rajendran JG, Petersdorf SH, et al. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 2002;99:3158.
54. Smith MR, Zhang L, Gordon LI, et al. Phase II study of RCHOP followed by 90Y- ibritumomab tiuxetan in untreated mantle cell lymphoma: Eastern Cooperative Oncology Group study E1499. Blood 2007;110:Abst 389.
55. Fisher RI, Kaminski MS, Wahl RL. Tositumomab and Iodine-131 Tositumomab produces durable complete remissions in a subset of heavily pretreated patients with lowgrade and transformed non-Hodgkin's lymphomas. J Clin Oncol 2005;23:7565.
56. Zelenetz AD, Abramson JS, Advani RH, et al. NCCN clinical practice guidelines in oncology: Non-Hodgkin's lymphomas. JNCI 2010;8:288.
57. Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory lowgrade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001;19:3918.
58. Witzig TE, Flinn IW, Gordon LI, et al. Treatment With ibritumomab tiuxetan radioimmunotherapy in patients with rituximab- refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002;20:3262.
59. Jurczak W, Giza A, Skotnicki AB, et al. Use of radioimmunotherapy for consolidation for chemosenstive mantle cell lymphoma (MCL): Summary of international radioimmunotherapy registry data. J Clin Oncol 2010;28(suppl): e18519.
60. Decaudin D, Mounier N, Tilly H, et al. (90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z-BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study. Clin Lymphoma Myeloma Leuk 2011;11:212.
61. Hohloch K, Sahlmann CO, Lakhani VJ, et al. Tandem highdose therapy in relapsed and refractory B-cell lymphoma: Results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with (131)I-anti-CD20 antibody and stem cell rescue. Ann Haematol 2011;90:1307.
62. Gopal AK, Rajendran JG, Gooley TA, et al. High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma. J Clin Oncol 2007;25:1396.
63. Behr TM, Griesinger F, Riggert J, et al. High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Results of a pilot study. Cancer 2002;94(suppl4):1363.
64. Turner JH, Martindale AA, Boucek J, et al. 131I-Anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkins lymphoma: A phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital. Cancer Biother Radiopharm 2003; 18:513.
65. Wolach O, Shpilberg O, Lahav M. Neutropenia after rituximab treatment: New insights on a late complication. Curr Opin Hematol 2012;19:32.
66. Cairoli R, Grillo G, Tedeschi A, et al. High incidence of neutropenia in patients treated with rituximab after autologous stem cell transplantation. Haematologica 2004; 89:361.
67. Voog E, Morschhauser F, Solal-Ce'ligny P. Neutropenia in patients treated with rituximab. N Engl J Med 2003;348: 2691.
68. Terrier B, Ittah M, Tourneur L, et al. Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery. Haematology 2007;92:e20.
69. Li SC, Chen YC, Evens AM, et al. Rituximab-induced late onset neutropenia in newly diagnosed B cell lymphoma correlates with Fc receptor Fc(gamma)RIIIa 158(V/F) polymorphism. Am J Hematol 2010;85:810.
70. Cooney J, Stiff P, Kaminski M. Successful autologous peripheral blood stem cell transplantation in transformed follicular lymphoma previously treated with radioimmunotherapy (iodine 131-I tositumomab). Bone Marrow Transplant 2002;29:523.
71. Bennett JM, Kaminski MS, Leonard JP, et al. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood 2005;105:4576.